IPSC supply chain intelligence for Century Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Century Therapeutics, Inc. (IPSC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FCDI | FCDI | 92% | On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran… |
| FUJIFILM-CELLULAR-DYNAMICS-INC | FUJIFILM-CELLULAR-DYNAMICS-INC | 92% | FCDI provides certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or … |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demo… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 90% | the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement |
| FCDI | FCDI | 90% | Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme… |
| BMYMP | Bristol-Myers Squibb Co | 72% | milestone payments upon the achievement of certain development and regulatory milestones up to an aggregate of $16.2 million or $12.15 million depending on the product. We additionally agreed to pay … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMYM… |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU g… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the dem… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| TCRX | TScan Therapeutics, Inc. | 72% | Reciprocal relationship from TCRX graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver… |
| COMPANY-LLC | COMPANY-LLC | 62% | or iPSC-derived allogeneic, cell therapy platforms; ● advance CNTY-813 and CNTY-308 through IND-enabling studies, submit IND applications and, if cleared, initiate and conduct clinical trials; ● cont… |
| FUJIFILM-CELLULAR-DYNAMICS-INC | FUJIFILM-CELLULAR-DYNAMICS-INC | 62% | hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif… |
| RHEINCELL-THERAPEUTICS-GMBH | RHEINCELL-THERAPEUTICS-GMBH | 62% | hospital processes are just beginning to be familiar and comfortable with their use. As a result, the execution and speed of enrollment of clinical trials in these novel and competitive areas are dif… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IPSC-DEBT | Debt stack $3.7M | 90% | Market cache reports total debt of $3.7M. |
| IPSC-DEBT-10342 | Warrants outstanding: 16112 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| IPSC-DEBT-10343 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P | RA CAPITAL MANAGEMENT, L.P. | 90% | 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CELUW | Celularity Inc | 100.00 | 1 | ['customer', 'supplier'] |
| FATE | Fate Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 |